Johnson & Johnson (JNJ) FCF Payout Ratio (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly FCF Payout Ratio came in at 2.14 in Q1 2026, up 141.61% year-on-year from 0.88 in Q1 2025, and up 273.52% quarter-over-quarter from 0.57 in Q4 2025.
Johnson & Johnson (JNJ) FCF Payout Ratio (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed FCF Payout Ratio across 18 years of filings, most recently posting 2.14 for Q1 2026.
- FCF Payout Ratio for Q1 2026 came in at 2.14, up 141.61% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.7 (up 20.11% YoY), and the FY2025 annual result was 0.63, up 5.49% from the prior year.
- FCF Payout Ratio came in at 2.14 for Q1 2026 at Johnson & Johnson, up from 0.57 in the prior quarter.
- In the past five years, FCF Payout Ratio ranged from a high of 2.14 in Q1 2026 to a low of 0.39 in Q3 2025.
- The 5-year median for FCF Payout Ratio is 0.83 (2022), against an average of 0.91.
- Across the five-year window, FCF Payout Ratio plunged 76.86% in 2023 and surged 141.61% in 2026, its largest moves.
- Johnson & Johnson's FCF Payout Ratio stood at 0.83 in 2022, then plunged by 44.75% to 0.46 in 2023, then increased by 21.66% to 0.56 in 2024, then increased by 2.99% to 0.57 in 2025, then surged by 273.52% to 2.14 in 2026.
- The last three FCF Payout Ratio figures came in at 2.14 (Q1 2026), 0.57 (Q4 2025), and 0.39 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -0.41 |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 0.51 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 0.87 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 0.72 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 0.92 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.43 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 1.12 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.69 |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 2.14 |
| Dec 28, 2025 | 0.57 |
| Sep 28, 2025 | 0.39 |
| Jun 29, 2025 | 1.10 |
| Mar 30, 2025 | 0.88 |
| Dec 29, 2024 | 0.56 |
| Sep 29, 2024 | 0.43 |
| Jun 30, 2024 | 0.64 |
| Mar 31, 2024 | 1.01 |
| Dec 31, 2023 | 0.46 |
| Oct 1, 2023 | 0.44 |
| Jul 2, 2023 | 1.01 |
| Apr 2, 2023 | 1.23 |
| Jan 1, 2023 | 1.97 |
| Apr 3, 2022 | 0.83 |
| Oct 3, 2021 | 0.37 |
| Jul 4, 2021 | 0.62 |
| Apr 4, 2021 | 0.78 |
| Jan 3, 2021 | 0.38 |
| Sep 27, 2020 | 0.35 |